Our news

• The production site of the Russian pharmaceutical company NovaMedica will be chosen in the 1st quarter of 2013

  13 November 2012

  The identification of location of the production site of a new pharmaceutical company NovaMedica, a joint enterprise betweenthe Russian high-technology investment fund RUSNANO and the American venture healthcare fund Domain Associates will be chosen at the end of the first quarter of 2013.

• Fabrice Egros has been appointed COO, Pharmaceutical Director and board member of NovaMedica, a novel pharmaceutical company

  12 November 2012

  

  Fabrice Egros was appointed as COO, Pharmaceutical Director and board member of NovaMedica a novel Russian pharmaceutical company, which was established within the frameworks of the joint project between RUSNANO and the American venture fund Domain Associates.

• Russian pharmaceutical company NovaMedica announces the opening of its US office

  12 November 2012

  NovaMedica, a company whose mission is commercializing highly innovative pharmaceutical products in Russia and the CIS, today announces the opening of its US office.

• Special autumn session for the pharmaceutical business leaders

  01 October 2012

  

  Vladimir Gurdus: In order to foster the development of an innovative pharmaceuticals sector in Russia, we need the support of a globally competitive cluster of venture investors in the sector here in Russia.

• Domain Associates & RUSNANO announce first joint investment

  24 July 2012

  

  Domain Associates, the Princeton, NJ- and San Diego, CA-based venture capital firm and RusnanoMedInvest (“RMI”, a subsidiary of RUSNANO) today announced their first investment under a joint agreement reached in March. The two will jointly invest nearly $40 million in San Diego, CA-based, CoDa Therapeutics, a Domain portfolio company, along with current investors GBS Ventures (Melbourne, Australia) and BioPacificVentures (Auckland, NZ). 

• St. Petersburg International Economic Forum

  21 June 2012

  

  Leonid Melamed: Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets

• RUSNANO and Domain to Collaborate on Investments in Health Sciences Projects

  06 March 2012

  

  RUSNANO and Domain Associates, a U.S. venture capital firm specializing in leading-edge life sciences technologies, today announced a partnership that will spur modernization of the Russian healthcare market by bringing next-generation pharmaceuticals, medical devices and diagnostics to Russia.